Logo image of GRO

BRAZIL POTASH CORP (GRO) Stock Fundamental Analysis

NYSEARCA:GRO - NYSE Arca - CA10586A1084 - Common Stock - Currency: USD

2.22  +0.1 (+4.72%)

After market: 2.45 +0.23 (+10.36%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to GRO. GRO was compared to 85 industry peers in the Chemicals industry. The financial health of GRO is average, but there are quite some concerns on its profitability. GRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GRO had negative earnings in the past year.
GRO Yearly Net Income VS EBIT VS OCF VS FCFGRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of GRO (-10.48%) is worse than 77.65% of its industry peers.
The Return On Equity of GRO (-11.10%) is worse than 74.12% of its industry peers.
Industry RankSector Rank
ROA -10.48%
ROE -11.1%
ROIC N/A
ROA(3y)-12.49%
ROA(5y)N/A
ROE(3y)-12.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRO Yearly ROA, ROE, ROICGRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -5 -10 -15 -20 -25

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRO Yearly Profit, Operating, Gross MarginsGRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, GRO has about the same amount of shares outstanding.
There is no outstanding debt for GRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRO Yearly Shares OutstandingGRO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M 40M
GRO Yearly Total Debt VS Total AssetsGRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 5.00 indicates that GRO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.00, GRO belongs to the top of the industry, outperforming 95.29% of the companies in the same industry.
GRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5
ROIC/WACCN/A
WACCN/A
GRO Yearly LT Debt VS Equity VS FCFGRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

GRO has a Current Ratio of 0.32. This is a bad value and indicates that GRO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of GRO (0.32) is worse than 91.76% of its industry peers.
A Quick Ratio of 0.32 indicates that GRO may have some problems paying its short term obligations.
GRO's Quick ratio of 0.32 is on the low side compared to the rest of the industry. GRO is outperformed by 91.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.32
Quick Ratio 0.32
GRO Yearly Current Assets VS Current LiabilitesGRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

GRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.51%, which is quite impressive.
EPS 1Y (TTM)59.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRO Price Earnings VS Forward Price EarningsGRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRO Per share dataGRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAZIL POTASH CORP

NYSEARCA:GRO (5/9/2025, 8:04:02 PM)

After market: 2.45 +0.23 (+10.36%)

2.22

+0.1 (+4.72%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.72%
Inst Owner Change5.01%
Ins Owners10.52%
Ins Owner ChangeN/A
Market Cap85.27M
Analysts80
Price Target5.61 (152.7%)
Short Float %0.29%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.1
TBVpS3.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.48%
ROE -11.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.49%
ROA(5y)N/A
ROE(3y)-12.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.32
Quick Ratio 0.32
Altman-Z 5
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.25%
OCF growth 3YN/A
OCF growth 5YN/A